Wockhardt LimitedNSE: WOCKPHARMA

Press Release Oct 01 2025

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited has submitted a New Drug Application to the U.S. FDA for Zidebactam-Cefepime, aimed at treating serious Gram-negative infections. This submission marks a significant milestone as it is the first NDA from an Indian pharmaceutical company for a drug fully discovered and developed in India. The drug targets complicated urinary tract infections caused by multidrug-resistant bacteria, addressing a growing global health crisis. The application follows successful Phase III clinical trials conducted across multiple countries, demonstrating the drug's efficacy against resistant infections.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime (WCK 5222) for Treatment of Serious Gram-Negative Infections .

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases